Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina

Antiviral Research

Volumn 87, Issue 1, 2010, Pages 74-77

  Cuestas, María L ^a   Rivero, Cintia W ^a,b   Minassian, María L ^a,b   Castillo, Amalia I ^a   Gentile, Emiliano A ^a   Trinks, Julieta ^a,b   León, Liliana ^c   Daleoso, Graciela ^c   Frider, Bernardo ^d   Lezama, Carol ^e   Galoppo, Marcela ^e   Giacove, Gisela ^e   Mathet, Verónica L ^a,b   Oubiña, José R ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c Servicio de Hemoterapia   (Argentina)

^d Htal Argerich   (Argentina)

^e Unidad 4 de Hepatologiand a   (Argentina)

Author keywords

Antivirals; Argentina; HBV; Naturally occurring resistance; S mutants

Indexed keywords

ADEFOVIR; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARGENTINA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CHOICE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH; SEQUENCE ANALYSIS; VIRUS MUTANT; VIRUS TRANSMISSION;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; ARGENTINA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES;

HEPATITIS B VIRUS;

EID: 77953545943     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.04.005     Document Type: Article

References (24)

1. Alvarado-Esquivel C., Sablon E., Conde-González C.J., Juárez-Figueroa L., Ruiz-Maya C., Aguilar-Benavides S. Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis B virus genotype H. World J. Gastroenterol. 2006, 12:6540-6545.
2. Borst A., Box A.T., Fluit A.C. False-positive results and contamination in nucleic acid amplification assays: suggestions for a prevent and destroy strategy. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:289-299.
3. Bottecchia M., Madejón A., Sheldon J., García-Samaniego J., Barreiro P., Soriano V. Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. J. Antimicrob. Chemother. 2008, 62:626-627.
4. Coleman P.F. Detecting hepatitis B surface antigen mutants. Emerg. Infect. Dis. 2006, 12:198-203.
5. Cuestas M.L., Mathet V.L., Ruiz V., Minassian M.L., Rivero C., Sala A., Corach D., Alessio A., Pozzati M., Frider B., Oubiña J.R. Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected Argentine patient with anti-HBs antibodies. J. Clin. Microbiol. 2006, 44:2191-2198.
6. Devesa M., Rodríguez C., León G., Liprandi F., Pujol F.H. Clade analysis and surface antigen polymorphism of hepatitis B virus American genotypes. J. Med. Virol. 2004, 72:377-384.
7. Felsenstein J. PHYLIP Inference Package Version 3.5 1993, Departments of Genetics, University of Washington, Seattle.
8. Ghany M., Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007, 132:1574-1585.
9. Gutiérrez C., Devesa M., Loureiro C.L., León G., Liprandi F., Pujol F.H. Molecular and serological evaluation of surface antigen negative hepatitis B virus infection in blood donors from Venezuela. J. Med. Virol. 2004, 73:200-207.
10. Jardí R., Rodriguez-Frias F., Schaper M., Ruiz G., Elefsiniotis I., Esteban R., Buti M. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naïve patients. J. Viral Hepat. 2007, 14:835-840.
11. Kim K.H., Lee K.H., Ahn S.H., Tong S., Yoon Y.J., Seong B.L., Kim S.I., Han K.H. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J. Med. Virol. 2003, 71:367-375.
12. Kwok S., Higuchi R. Avoiding false positives with PCR. Nature 1989, 339:237-238.
13. Lai M.W., Yeh C.T. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antiv. Ther. 2008, 13:875-879.
14. Liu, B.-M., Li, T., Xu, Li, X.-G., Dong, J.-P., Yang, J.-X., Yan, L., Gao, Z.-Y., Li, W.-P, Sun, X.-W., Wang, Y.-H., Jiao, X.-J., Hou, C.-S., Zhuang, H., 2010. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment naive Chinese patients with chronic hepatitis B. Antiviral Res. 85, 512-519.
15. Locarnini S.A. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998, 27:294-297.
16. Mathet V.L., Feld M., Espínola L., Sánchez D.O., Ruiz V., Mandó O., Carballal G., Quarleri J., D'Mello F., Howard C.R., Oubiña J.R. Hepatitis B virus S gene mutants in a patient with chronic active hepatitis with circulating anti-HBs antibodies. J. Med. Virol. 2003, 69:18-26.
17. Mathet V.L., Cuestas M.L., Ruiz V., Minassian M.L., Rivero C., Trinks J., Daleoso G., León L.M., Sala A., Libellara .B., Corach D., Oubiña J.R. Detection of Hepatitis B virus (HBV) genotype E carried - even in the presence of high titers of anti-HBs antibodies - by an Argentinean patient of African descent who had received vaccination against HBV. J. Clin. Microbiol. 2006, 44:3435-3439.
18. Niesters H.G., Pas S., de Man R.A. Detection of hepatitis B virus genotypes and mutants: current status. J. Clin. Virol. 2005, S4-S8.
19. Norder H., Couroucé A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushakwar I.K., Robertson B.H., Locarnini S., Magnius L.O. Genetic diversity of Hepatitis B virus strains derived worldwide: genoytpes, subgenotypes, and HBs Ag subtypes. Intervirology 2004, 47:289-309.
20. Ono-Nita S.K., Kato N., Shiratori Y., Masaki T., Lan K.-H., Carrilho F.J., Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999, 29:939-945.
21. Sánchez L.V., Maldonado M., Bastidas-Ramírez B.E., Norder H., Panduro A. Genotypes and S-variability of Mexican hepatitis B virus strains. J. Med. Virol. 2002, 68:24-32.
22. Schildgen O., Schewe C.K., Vogel M., Däumer M., Kaiser R., Weitner L., Matz B., Rockstroh J.K. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004, 18:2325-2327.
23. Shields P.L., Owsianka A., Carman W.F., Boxall E., Hubscher S.G., Shaw J., O'Donnell K. Selection of hepatitis B surface " escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Gut 1999, 45:306-309.
24. Tanaka Y., Yeo A.E., Orito E., Ito K., Hirashima N., Ide T., Sata M., Mizokami M. Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection. J. Gastroenterol. 2004, 39:769-775.